ArticleJournal of medical cases2026
Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody Vasculitis With Isolated Renal Presentation in an Older Female Patient: A Diagnostic and Therapeutic Challenge.
Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic autoimmune diseases, the incidence of which increases in older individuals. We report the case of a 76-year-old woman whose routine laboratory workup revealed acute kidney injury with a serum creatinine level of 155 µmol/L and significant proteinuria (2.5 g/24 h). ANCA testing was strongly positive for anti-myeloperoxidase (MPO) antibodies. A renal biopsy confirmed pauci-immune glomerulonephritis with moderate interstitial fibrosis and glomerulosclerosis, consistent with ANCA-associated vasculitis. Induction therapy consisted of corticosteroids and rituximab, which was discontinued following a suspected drug-related cutaneous reaction. Cyclophosphamide was successfully used as an alternative induction treatment. Following negative allergological evaluation and cautious re-exposure, rituximab was subsequently resumed for maintenance therapy and was well tolerated. Late-onset MPO-ANCA-associated vasculitis can have a favorable prognosis when diagnosed early and managed with appropriate immunosuppressive regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.